OraPharma, Inc.
732 Louis Dr.
Warminster, PA 18974
Phone: 215-956-2200
Fax: 215-443-9531
orapharma.com
OraPharma wants to save your toothy grin. The
development-stage company's Minocycline
Periodontal Therapeutic System (MPTS) is
aimed at wiping out periodontitis, a leading
cause of adult tooth loss. Using a polymer
microsphere delivery system licensed from
American Home Products subsidiary American
Cyanamid, MPTS delivers a sustained dose of
antibiotic to an infection site after plaque
removal. The company is also developing a
treatment for oral mucositis (a condition that
occurs frequently in patients receiving
chemotherapy or radiation therapy) and a
therapy for bone and soft-tissue regeneration.
The company is owned by a group of
investment firms that includes Oak Investment
Partners and Canaan Partners.
Top Competitors
Atrix Labs | CollaGenex Pharmaceuticals | Perio Products
IPO Information
Filing Date: Dec 30, 1999
Expected IPO Date: Mar 6, 2000
Proposed offer price: $15.00 to $17.00
Shares offered (mil.): 4.0
Offering amount (mil.): $64.0
Post-offering shares (mil.): 12.6
Underwriters:
Robertson, Stephens & Company; U.S.
Bancorp Piper Jaffray; Gerard Klauer Mattison
& Co., Inc. |
